Avoid in patients with impaired kidney function
In patients with Type 2 DM and established HF, this may be considered to reduce risk of HF hospitalization
Increases loss of glucose in urine
Stimulates insulin secretion
Decreases appetite
Slows gastric emptying
Reduces glucose reabsorption
Recommended to reduce CV risk in patient with Type 2 DM & established ASCVD
Suppresses glucagon secretion
Trulicity, Byetta, Bydureon, Victoza, Ozempic
Invokana, Farxiga, Jardiance
Use with caution in patients receiving higher dose diuretics